Niraparib maintenance therapy in patients with platinum-sensitive recurrent ovarian cancer using an individualized starting dose (NORA): a randomized, double-blind, placebo-controlled phase III trial☆

Phase Iii ◽

Double Blind ◽

Phase Iii Trial ◽

Double Blind Placebo ◽

Platinum Sensitive ◽

LBA29 Individualized starting dose of niraparib in Chinese patients with platinum-sensitive recurrent ovarian cancer (PSROC): A randomized, double-blind, placebo-controlled, phase III trial (NORA)

Annals of Oncology ◽

10.1016/j.annonc.2020.08.2259 ◽

2020 ◽

Vol 31 ◽

pp. S1160-S1161

Author(s):

X. Wu ◽

J. Zhu ◽

R. Yin ◽

J. Yang ◽

J. Liu ◽

...

Keyword(s):

Ovarian Cancer ◽

Phase Iii ◽

Chinese Patients ◽

Double Blind ◽

Phase Iii Trial ◽

Double Blind Placebo ◽

Platinum Sensitive ◽

235O Efficacy and safety of niraparib in Chinese patients with platinum-sensitive recurrent ovarian cancer (NORA) with individualized starting dose: A subgroup analysis of a randomized, double-blind, placebo-controlled, phase III trial

Annals of Oncology ◽

10.1016/j.annonc.2020.10.229 ◽

2020 ◽

Vol 31 ◽

pp. S1335

Author(s):

X. Wu ◽

J. Zhu ◽

R. Yin ◽

J. Yang ◽

J. Liu ◽

...

Keyword(s):

Ovarian Cancer ◽

Phase Iii ◽

Chinese Patients ◽

Efficacy And Safety ◽

Double Blind ◽

Phase Iii Trial ◽

Double Blind Placebo ◽

Platinum Sensitive ◽

Fuzuloparib maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer: a multicenter, randomized, double-blind, placebo-controlled, phase III trial

Gynecologic Oncology ◽

10.1016/s0090-8258(21)00752-6 ◽

2021 ◽

Vol 162 ◽

pp. S57-S58

Author(s):

Ning Li ◽

Youzhong Zhang ◽

Jing Wang ◽

Jianqing Zhu ◽

Li Wang ◽

...

Keyword(s):

Ovarian Cancer ◽

Maintenance Therapy ◽

Phase Iii ◽

Double Blind ◽

Phase Iii Trial ◽

Double Blind Placebo ◽

Niraparib maintenance therapy in patients with platinum-sensitive recurrent ovarian cancer and a time-to-progression after penultimate platinum-based chemotherapy of 6-12 or >12 months: a subgroup analysis of the phase III NORA trial

Gynecologic Oncology ◽

10.1016/s0090-8258(21)00681-8 ◽

2021 ◽

Vol 162 ◽

pp. S18

Author(s):

Qidan Huang ◽

Xiaohua Wu ◽

Jianqing Zhu ◽

Danqing Wang ◽

Jiaxin Yang ◽

...

Keyword(s):

Ovarian Cancer ◽

Maintenance Therapy ◽

Subgroup Analysis ◽

Phase Iii ◽

Time To Progression ◽

Platinum Sensitive ◽

Platinum Based Chemotherapy

LBA31 Primary results from IMagyn050/GOG 3015/ENGOT-OV39, a double-blind placebo (pbo)-controlled randomised phase III trial of bevacizumab (bev)-containing therapy +/- atezolizumab (atezo) for newly diagnosed stage III/IV ovarian cancer (OC)

Annals of Oncology ◽

10.1016/j.annonc.2020.08.2261 ◽

2020 ◽

Vol 31 ◽

pp. S1161-S1162 ◽

Cited By ~ 1

Author(s):

K.N. Moore ◽

M. Bookman ◽

J. Sehouli ◽

A. Miller ◽

C. Anderson ◽

...

Keyword(s):

Ovarian Cancer ◽

Phase Iii ◽

Stage Iii ◽

Newly Diagnosed ◽

Double Blind ◽

Phase Iii Trial ◽

Double Blind Placebo

Real world occurrence of top three clinical-trial reported adverse events of PARP inhibitor niraparib maintenance therapy in platinum-sensitive, recurrent ovarian cancer, a national retrospective observational study of a 200 mg/day starting-dose cohort

Annals of Oncology ◽

10.1093/annonc/mdy285.193 ◽

2018 ◽

Vol 29 ◽

pp. viii351-viii352

Author(s):

J.R. Gallagher ◽

K.J. Heap ◽

S. Carroll

Keyword(s):

Ovarian Cancer ◽

Clinical Trial ◽

Adverse Events ◽

Observational Study ◽

Maintenance Therapy ◽

Parp Inhibitor ◽

Dose Cohort ◽

Platinum Sensitive ◽

Faculty Opinions recommendation of OCEANS: a randomized, double-blind, placebo-controlled phase III trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent epithelial ovarian, primary peritoneal, or fallopian tube cancer.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.716997867.792703133 ◽

2012 ◽

Author(s):

Sandro Pignata ◽

Sabrina Cecere

Keyword(s):

Fallopian Tube ◽

Phase Iii ◽

Fallopian Tube Cancer ◽

Double Blind ◽

Phase Iii Trial ◽

Double Blind Placebo ◽

Faculty Opinions recommendation of OCEANS: a randomized, double-blind, placebo-controlled phase III trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent epithelial ovarian, primary peritoneal, or fallopian tube cancer.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.716997867.793485306 ◽

2013 ◽

Author(s):

Maurie Markman

Keyword(s):

Fallopian Tube ◽

Phase Iii ◽

Fallopian Tube Cancer ◽

Double Blind ◽

Phase Iii Trial ◽

Double Blind Placebo ◽

Gemcitabine/carboplatin (GC) vs. carboplatin (C) in platinum sensitive recurrent ovarian cancer (OVCA). Results of a Gynecologic Cancer Intergroup randomized phase III trial of the AGO OVAR, the NCIC CTG and the EORTC GCG

Journal of Clinical Oncology ◽

10.1200/jco.2004.22.14_suppl.5005 ◽

2004 ◽

Vol 22 (14_suppl) ◽

pp. 5005-5005 ◽

Cited By ~ 21

Author(s):

J. Pfisterer ◽

M. Plante ◽

I. Vergote ◽

A. Du Bois ◽

U. Wagner ◽

...

Keyword(s):

Ovarian Cancer ◽

Gynecologic Cancer ◽

Phase Iii ◽

Phase Iii Trial ◽

Efficacy and safety of chemotherapy (CT) ± pertuzumab (P) for platinum-resistant ovarian cancer (PROC): AGO-OVAR 2.20/ENGOT-ov14/PENELOPE double-blind placebo-controlled randomized phase III trial.

Journal of Clinical Oncology ◽

10.1200/jco.2015.33.15_suppl.5504 ◽

2015 ◽

Vol 33 (15_suppl) ◽

pp. 5504-5504 ◽

Cited By ~ 3

Author(s):

Christian Kurzeder ◽

Isabel Bover ◽

Frederik Marmé ◽

Joern Rau ◽

Patricia Pautier ◽

...

Keyword(s):

Ovarian Cancer ◽

Phase Iii ◽

Efficacy And Safety ◽

Double Blind ◽

Phase Iii Trial ◽

Double Blind Placebo ◽

Platinum Resistant